Log in
Log in
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
Sign up
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
  1. Homepage
  2. Equities
  3. Denmark
  4. Nasdaq Copenhagen
  5. Novo Nordisk A/S
  6. News
  7. Summary
    NOVO B   DK0060534915

NOVO NORDISK A/S

(NOVO B)
  Report
Delayed Nasdaq Copenhagen  -  10:59 2022-09-23 am EDT
749.30 DKK   +0.92%
09/22Novo Nordisk Says Phase 3a Trial of Once-Weekly Insulin Icodec Met Primary Endpoint
MT
09/22Novo Nordisk's Trial Finds Weekly Insulin More Effective Than Daily Insulin Jabs
MT
09/21European ADRs Move Lower in Wednesday Trading
MT
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisionsFunds 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

NOVO NORDISK : Buy rating from Deutsche Bank

08/05/2022 | 05:16am EDT

Already positive, the research from Deutsche Bank and its analyst Emmanuel Papadakis still consider the stock as a Buy opportunity. The target price remains unchanged at DKK 1000.


© MarketScreener with dpa-AFX Analyser 2022
All news about NOVO NORDISK A/S
09/22Novo Nordisk Says Phase 3a Trial of Once-Weekly Insulin Icodec Met Primary Endpoint
MT
09/22Novo Nordisk's Trial Finds Weekly Insulin More Effective Than Daily Insulin Jabs
MT
09/21European ADRs Move Lower in Wednesday Trading
MT
09/21NOVO NORDISK : Deutsche Bank remains its Buy rating
MD
09/20Octagon Therapeutics Enters Inflammation-Focused Research Alliance with Novo Nordisk
CI
09/19Novo Nordisk A/S – Share repurchase programme
GL
09/19Novo Nordisk A/S – Share repurchase programme
GL
09/14TRANSCRIPT : Novo Nordisk A/S Presents at JP Morgan EU Healthcare CEO Conference Calls Ser..
CI
09/12Novo Nordisk A/S – Share repurchase programme
GL
09/12Novo Nordisk A/S – Share repurchase programme
GL
More news
Analyst Recommendations on NOVO NORDISK A/S
More recommendations
Financials
Sales 2022 171 B 22 410 M 22 410 M
Net income 2022 54 524 M 7 131 M 7 131 M
Net cash 2022 969 M 127 M 127 M
P/E ratio 2022 30,8x
Yield 2022 1,55%
Capitalization 1 696 B 222 B 222 B
EV / Sales 2022 9,89x
EV / Sales 2023 8,64x
Nbr of Employees 50 816
Free-Float 69,6%
Chart NOVO NORDISK A/S
Duration : Period :
Novo Nordisk A/S Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends NOVO NORDISK A/S
Short TermMid-TermLong Term
TrendsBearishNeutralBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 26
Last Close Price 749,30 DKK
Average target price 829,92 DKK
Spread / Average Target 10,8%
EPS Revisions
Managers and Directors
Lars Fruergaard Jørgensen President & Chief Executive Officer
Karsten Munk Knudsen Chief Financial Officer & Executive Vice President
Helge Lund Chairman
Henrik Ehlers Wulff Senior Vice President-Diabetes API
Stephen Gough Global Chief Medical Officer
Sector and Competitors
1st jan.Capi. (M$)
NOVO NORDISK A/S1.95%221 838
JOHNSON & JOHNSON-2.54%438 337
ELI LILLY AND COMPANY12.54%295 941
ROCHE HOLDING AG-18.41%259 291
ABBVIE INC.5.66%252 944
PFIZER, INC.-25.35%247 392